| CD80、CD83、CD86检测在非小细胞肺癌中的应用价值 |
| |
| 引用本文： | 喻长法,叶丽君,蔡莎莎,鲍建敏,张绍文.CD80、CD83、CD86检测在非小细胞肺癌中的应用价值[J].中华全科医学,2018,16(8):1342. |
| |
| 作者姓名： | 喻长法 叶丽君 蔡莎莎 鲍建敏 张绍文 |
| |
| 作者单位： | 1. 台州市第一人民医院检验科, 浙江 台州 318020; |
| |
| 基金项目： | 浙江省中医药科技计划项目(2012ZB172) |
| |
| 摘 要： | 目的 探讨CD80、CD83、CD86检测在非小细胞肺癌(NSCLC)中的临床意义。 方法 收集2012年1月-2015年12月在台州市第一人民医院治疗的NSCLC患者113例及健康对照组30例。采用流式细胞术分析NSCLC患者和健康对照者外周血CD80、CD83、CD86的表达水平。数据比较采用t检验和方差分析,患者生存时间采用Kaplan-Meier法和log-rank分析来确定是否有差异。 结果 NSCLC患者CD80、CD83、CD86水平明显低于正常对照组(t=10.026、4.963、4.870,均P<0.05),不同分期患者CD80、CD83水平差异有统计学意义(F=12.750、9.481,均P<0.05)。NSCLC患者术后CD80、CD83、CD86水平较术前明显升高(t=-3.648、-4.621、-4.257,均P<0.05)。CD80水平较高的NSCLC患者具有更好的生存率(P=0.040),而CD83、CD86水平与生存率无关(P=0.118、0.084)。 结论 检测NSCLC患者CD80、CD83、CD86水平具有一定价值,CD80、CD83与肿瘤分期密切相关,且CD80是NSCLC患者生存时间的独立预测因子。
|
| 关 键 词： | 非小细胞肺癌 CD80 CD83 CD86 |
| 收稿时间： | 2017-04-07 |
The application value of CD80, CD83, CD86 in patients with non-small cell lung cancer |
| |
| Affiliation: | Department of Laboratory Medicine, the First People's Hospital of Taizhou, Taizhou, Zhejiang 318020, China |
| |
| Abstract: | Objective To investigate the clinical significance of CD80, CD83 and CD86 of non-small cell lung cancer (NSCLC) patients. Methods One hundred and thirteen cases of patients with NSCLC and 30 cases of healthy controls from January, 2012 to December, 2015 in the first people's hospital of Taizhou were collected.The expression of CD80, CD83 and CD86 in the peripheral blood of patients with NSCLC and healthy controls were analyzed by flow cytometry. Comparisons were made using the t test and variance test. Kaplan-Meier plots and log rank analysis were applied to determine the significance of differences in patient's survival time. Results The levels of CD80, CD83, CD86 in NSCLC patients were significantly lower than those of normal controls (t=10.026, 4.963, 4.870, all P<0.05), and CD80, CD83 were significantly difference in different TNM stage (F=12.750, 9.481, all P<0.05). The levels of CD80, CD83 and CD86 in NSCLC patients after operation were significantly improved than that before operation (t=-3.648, -4.621, -4.257, all P<0.05). The NSCLC patients with high level of CD80 had better survival rate (P=0.040), while CD83 and CD86 had not (P=0.118, 0.084). Conclusion The detection of CD80, CD83 and CD86 may be valuable in NSCLC patients. CD80, CD83 are closely associated with TNM stage, and CD80 is an independent predictor of survival time. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
